Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 250

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 250
---
 are received from the exercise of the Exchange
Warrants, assuming that the Exchange Warrants are exercised in full at an exercise price of $1.8258. The foregoing is subject to adjustment
as set forth in the respective Notes and Warrants, as applicable.

<div align='center'>II-3</div>

On November 21, 2024, the
Company entered into a Common Shares Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC
(“White Lion”) and a related Registration Rights Agreement (the “RRA”). Pursuant to the White Lion Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars
($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to Three Hundred Million
Dollars ($300,000,000) upon any substantial M&A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further
option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been
issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the
White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration statement
filed on December 5, 2024.

On December 10, 2024, 700,000
Class A Ordinary Shares (equivalent to 700 Class A Ordinary Shares post Reverse Stock Splits) were issued to White Lion, in consideration
for White Lion’s commitment pursuant to the White Lion Purchase Agreement. Between December 12, 2024 and August 5, 2025, the Company
received gross proceeds of $11,659,051 and issued an aggregate of 1,108,600 Class A Ordinary Shares (on a post-Reverse Stock Splits basis)
to White Lion.

On January 21, 2025, the Company
entered into a Purchase Agreement with Genetics & IVF Institute, Inc. (“Purchase Agreement”), pursuant to which the Company
purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to
the MicroSort Business (as defined in the Purchase Agreement) from Genetics & IVF Institute, Inc. for a